Mexiletine as a treatment for primary erythromelalgia: Normalization of biophysical properties of mutant L858F NaV1.7 sodium channels

British Journal of Pharmacology

Volumn 171, Issue 19, 2014, Pages 4455-4463

  Cregg, R ^a,b   Cox, J J ^a   Bennett, D L H ^c   Wood, J N ^a   Werdehausen, R ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Department of Orthopedic Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MEXILETINE; SODIUM CHANNEL NAV1.7; VOLTAGE GATED SODIUM CHANNEL BETA 1 SUBUNIT; VOLTAGE GATED SODIUM CHANNEL BETA 2 SUBUNIT; ANALGESIC AGENT; SCN9A PROTEIN, HUMAN; SODIUM CHANNEL BLOCKING AGENT;

AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; BIOPHYSICS; CELL MEMBRANE DEPOLARIZATION; CELL MEMBRANE POTENTIAL; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ERYTHROMELALGIA; GAIN OF FUNCTION MUTATION; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HYPERPOLARIZING POTENTIAL; IC50; IN VITRO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIMARY ERYTHROMELALGIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; SODIUM CURRENT; VOLTAGE CLAMP TECHNIQUE; VOLTAGE DEPENDENCE OF STEADY STATE ACTIVATION; VOLTAGE DEPENDENCE OF STEADY STATE FAST INACTIVATION; WHOLE CELL PATCH CLAMP; WILD TYPE; DRUG EFFECTS; GENETICS; MUTATION; PATCH CLAMP TECHNIQUE; PHYSIOLOGY;

ANALGESICS; ERYTHROMELALGIA; HEK293 CELLS; HUMANS; ION CHANNEL GATING; MEXILETINE; MUTAGENESIS, SITE-DIRECTED; MUTATION; NAV1.7 VOLTAGE-GATED SODIUM CHANNEL; PATCH-CLAMP TECHNIQUES; SODIUM CHANNEL BLOCKERS;

EID: 84927702744     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12788     Document Type: Article

References (37)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, and, Harmar AJ, CGTP Collaborators. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1646.
2. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB, (2005). Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev (4): CD003345.
3. Cheng X, Dib-Hajj SD, Tyrrell L, Te Morsche RH, Drenth JPH, Waxman SG, (2011). Deletion mutation of sodium channel Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability. Brain 134: 1972-1986.
4. Chevrier P, Vijayaragavan K, Chahine M, (2004). Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol 142: 576-584.
5. Chew CY, Collett J, Singh BN, (1979). Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs 17: 161-181.
6. Choi J-S, Zhang L, Dib-Hajj SD, Han C, Tyrrell L, Lin Z, et al. (2009). Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off. Exp Neurol 216: 383-389.
7. Courtney KR, (1981). Comparative actions of mexiletine on sodium channels in nerve, skeletal and cardiac muscle. Eur J Pharmacol 74: 9-18.
8. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, et al. (2006). An SCN9A channelopathy causes congenital inability to experience pain. Nature 444: 894-898.
9. Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, et al. (2005). Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128: 1847-1854.
10. Ebell MH, (2006). Systemic lidocaine or mexiletine for neuropathic pain. Am Fam Physician 74: 79.
11. Errington AC, Stöhr T, Heers C, Lees G, (2008). The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73: 157-169.
12. Estacion M, Han C, Choi J-S, Hoeijmakers JGJ, Lauria G, Drenth JPH, et al. (2011). Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7. Mol Pain 7: 92.
13. Fenster PE, Comess KA, (1986). Pharmacology and clinical use of mexiletine. Pharmacotherapy 6: 1-9.
14. Fischer TZ, Gilmore ES, Estacion M, Eastman E, Taylor S, Melanson M, et al. (2009). A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol 65: 733-741.
15. Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Wang Y, et al. (2006). Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol 59: 553-558.
16. Han C, Lampert A, Rush AM, Dib-Hajj SD, Wang X, Yang Y, et al. (2007). Temperature dependence of erythromelalgia mutation L858F in sodium channel Nav1.7. Mol Pain 3: 3.
17. Jarvis B, Coukell AJ, (1998). Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 56: 691-707.
18. Kuhnert SM, Phillips WJ, Davis MD, (1999). Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol 135: 1447-1449.
19. Legroux-Crespel E, Sassolas B, Guillet G, Kupfer I, Dupre D, Misery L, (2003). [Treatment of familial erythermalgia with the association of lidocaine and mexiletine]. Ann Dermatol Venereol 130: 429-433.
20. Liu P, Jo S, Bean BP, (2012). Modulation of neuronal sodium channels by the sea anemone peptide BDS-I. J Neurophysiol 107: 3155-3167.
21. Mao J, Chen LL, (2000). Systemic lidocaine for neuropathic pain relief. Pain 87: 7-17.
22. Marmura MJ, (2010). Intravenous lidocaine and mexiletine in the management of trigeminal autonomic cephalalgias. Curr Pain Headache Rep 14: 145-150.
23. Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, et al. (2010). The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 133: 9-22.
24. Middleton D, (1980). Baseline pharmacology, electrophysiology and pharmacokinetics of mexiletine. Acta Cardiol Suppl: 45-53.
25. Monk JP, Brogden RN, (1990). Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 40: 374-411.
26. Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K, (2005). Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics 115: e504-e507.
27. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-1106.
28. Samuels ME, te Morsche RHM, Lynch ME, Drenth JPH, (2008). Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythermalgia. Mol Pain 4: 21.
29. Segerdahl AR, Xie J, Paterson K, Ramirez JD, Tracey I, Bennett DLH, (2012). Imaging the neural correlates of neuropathic pain and pleasurable relief associated with inherited erythromelalgia in a single subject with quantitative arterial spin labelling. Pain 153: 1122-1127.
30. Sheets PL, Jarecki BW, Cummins TR, (2011). Lidocaine reduces the transition to slow inactivation in Na(v)1.7 voltage-gated sodium channels. Br J Pharmacol 164: 719-730.
31. Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, et al. (2012). Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 308: 1357-1365.
32. Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB, (2005). Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg 101: 1738-1749.
33. Waxman SG, (2013). Painful Na-channelopathies: an expanding universe. Trends Mol Med 19: 406-409.
34. Woosley RL, Wang T, Stone W, Siddoway L, Thompson K, Duff HJ, et al. (1984). Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. Am Heart J 107: 1058-1065.
35. Wu M-T, Huang P-Y, Yen C-T, Chen C-C, Lee M-J, (2013). A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PLoS ONE 8: e55212.
36. Yang Y, Dib-Hajj SD, Zhang J, Zhang Y, Tyrrell L, Estacion M, et al. (2012). Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel. Nat Commun 3: 1186.
37. Zhao J, Duprè N, Puymirat J, Chahine M, (2012). Biophysical characterization of M1476I, a sodium channel founder mutation associated with cold-induced myotonia in French Canadians. J Physiol (Lond) 590: 2629-2644.